Commenting on the financial results for 2002, Jörg Täubel Managing Director, stated:“It has been an excellent year for Richmond Pharmacology. The level of bookings for trials has continued to grow throughout our first year, and we have doubled our capacity for volunteers accordingly. We are delighted to announce that at the end of our first year of trading we exceeded all expectations in terms of studies completed and by showing profitability.“With good order books and detailed plans to accommodate more trials through the coming year, we are well positioned for another year of profitable growth for Richmond Pharmacology.”

Latest news

Patient safety is not an afterthought. Explore our new infographic!

September 17, 2025
Patient safety is not an afterthought; it is the foundation of every clinical trial.
Read more

Events

JSCPT 2025

5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event